CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tanvex BioPharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tanvex BioPharma Inc
Floor 4, Willow House, Cricket Square,
P O BOX 2804
GRAND CAYMAN, KY1-1112  Cayman Islands Ticker: 65416541

Business Summary
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Lin ChengChen 2/6/2024 5/15/2015
Chief Financial Officer WenzhongYe 11/13/2023 11/1/2023
Deputy General Manager-LJB Production Development HelenaMakagiansar 3/12/2014 3/12/2014
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TANVEX BIOLOGICS CORP 2030 MAIN ST #520 IRVINE CA US
Tanvex BioPharma USA, Inc. 10421 Pacific Center Court San Diego CA United States

Business Names
Business Name
6541
Tanvex BioPharma USA, Inc.

General Information
Outstanding Shares: 133,962,867 (As of 3/21/2024)
Shareholders: 15,752
Stock Exchange: TPE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024